Trials for New MS Treatment Bring Hope of Remission to Patients

Recent trials involving high-dose immunosuppressive therapy has shown promise in being effective in promoting long-term remission for multiple sclerosis patients. Multiple Sclerosis (MS) attacks the central nervous system and is classified as an autoimmune disease.

After 5 years trials have shown that 69% those patients who have had a transplant of their own blood-forming cells followed by the aforementioned immunosuppressive therapy have shown no advancement in their disability. The trial, known as HALT-MS had the support of the National Institute of Allergy and Infectious Diseases (NIAID) and was conducted by the Immune Tolerance Network (ITN) that they fund.

Those participating in the trial did not take any other medications for MS after the HDIT/HCT (High-Dose Immunosuppressive Therapy and autologous Hematopoietic Cell Transplant), demonstrating that this therapy has a higher success rate than current MS treatments. “Although further evaluation of the benefits and risks of HDIT/HCT is needed” Richard Nash, M.D., of Colorado Blood Cancer Institute and one of the heads of the HALT-MS study, was quoted as saying “These five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS.”

There will be larger follow-up studies to confirm the results, and if the same outcomes are observed the treatment will likely be pushed forward to aid those patients that are either unresponsive to current therapies, or who may be thought to benefit from HDIT/HCT.

Dr. Shiva Gopal Vasishta is one of the doctors following this project very closely and specializes in caring for those with complex neurologically based cases, including those involving multiple sclerosis and other auto-immune diseases. Graduating in 1979 Dr. Shiva Gopal Vasishta has 38 years of experience in the industry and continues to stay on top of the most advanced treatments and studies.

Dr. Shiva Gopal Vasishta practices out of Voorhees, New Jersey under license #25MA55133, NPI #1932269982 and can be contacted at (856) 651-0060. His practice is centered in service to the health of his patients, allowing him to accept medicare assignments at the rate offered, meaning no surprise billings for his medicare patients. Those seeking further information can call directly, or visit Dr. Shiva Gopal Vasishta’s office at 2301 Evesham Road, Pavilion 800 Suite 209, Voorhees, New Jersey.